Copyright
©The Author(s) 2021.
World J Virol. Nov 25, 2021; 10(6): 312-325
Published online Nov 25, 2021. doi: 10.5501/wjv.v10.i6.312
Published online Nov 25, 2021. doi: 10.5501/wjv.v10.i6.312
Ref. | Details on study cohort | Univariate analysis for predictors of death | Multivariate analysis for predictors of death |
Regalado-Artamendi et al[40], 2021 | Lymphoma patients | Age ≥ 70 yr | Age ≥ 70 yr |
Comorbidities | Comorbidities | ||
CURB65 ≥ 3 | CURB ≥ 2 | ||
Low platelet count | Active disease | ||
Low hemoglobin level | |||
High D-dimer | |||
C-reactive protein >10 mg/dL | |||
LDH > 300 U/L | |||
Active disease1 (reference to CR) | |||
DLBCL histology (reference to FL) | |||
High-risk lymphoma2 (reference to low risk) | |||
Lamure et al[39], 2020 | Hospitalized lymphoma patients | Age ≥ 70 yr | Age ≥ 70 yr |
Hypertension | Active disease | ||
Previous cancer | |||
Bendamustine treatment | |||
Active disease |
- Citation: Bonuomo V, Ferrarini I, Dell'Eva M, Sbisà E, Krampera M, Visco C. COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review. World J Virol 2021; 10(6): 312-325
- URL: https://www.wjgnet.com/2220-3249/full/v10/i6/312.htm
- DOI: https://dx.doi.org/10.5501/wjv.v10.i6.312